Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
NORTHBROOK, Ill., Sept. 5, 2014 /PRNewswire/ -- Astellas announces today the data that will be presented on the anti-fungal isavuconazole at the 4th Interscience Conference on Antimicrobial Agents...
Read more about Astellas to Showcase Isavuconazole Data at ICAAC
NORTHBROOK, Ill., Sept. 2, 2014 /PRNewswire/ -- Astellas has appointed James Kellerman as the vice president of intellectual property (IP) in the Americas. Kellerman will report directly to Linda...
NORTHBROOK, Ill., July 31, 2014 /PRNewswire/ -- Astellas has appointed Moyra Knight as the head of corporate and employee communications in the Americas region. Knight will report directly to Jeff...
If isavuconazole is approved for invasive candidiasis, QIDP status provides a five-year extension of market exclusivity. NORTHBROOK, Ill., July 16, 2014 /PRNewswire/ -- Astellas today announced...
NORTHBROOK, Ill., July 9, 2014 /PRNewswire/ -- Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for...
Follow U.S. news
